IGF1 and hepatocellular carcinoma: To further examine the potential suppressive effect of niclosamide on the IGF-1R protein phosphorylation in sorafenib-resistant HCC cells, the sorafenib-resistant Hep2215_R and Hep3B_R HCC cells were treated with IGF-1 (50 ng/mL) with or without the presence of sorafenib (10 μM).